Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

(Yicai) Jan. 3 -- US pharma giant Eli Lilly’s Tirzepatide injection for blood sugar control and weight loss is now available ...

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...

The Food and Drug ... calorie diet and increased physical activity, the FDA noted in a release. An estimated 80 million patients in the U.S. experience the disease, according to Eli Lilly.

Eli Lilly's Zepbound is set to dominate the global obesity market, offering new hope with its groundbreaking treatment for ...

He now oversees Eli Lilly’s pipeline of incretin medications, including its blockbuster weight-loss drug Zepbound. Now, recent studies and clinical trials have found that these drugs also have ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY ...

Musk revealed using Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, highlighting their popularity for weight management.